Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours.
We evaluated three markers (insulin-like growth factor II (IGF-II), cyclooxygenase-2 (COX-2) and ets-1) of thyroid growth stimulation and cell transformation together with a thyroid-specific marker (thyroglobulin (Tg)) for their potential to differentiate benign and malignant follicular thyroid neoplasia (FN).



mRNA expression levels were determined by real-time PCR in 100 snap-frozen thyroid samples: 36 benign thyroid nodules with different histology and function (19 cold (CTN) and 17 toxic thyroid nodules (TTN)), 36 corresponding normal thyroid tissues of the same patients, eight Graves' disease (GD) thyroids, 10 follicular thyroid carcinomas (FTC) and 10 papillary thyroid carcinomas (PTC).



Mean IGF-II and COX-2 levels were not significantly altered between benign and malignant thyroid nodules (IGF-II) or nodular (FTC, TTN, CTN) and normal thyroid tissues (COX-2). In contrast, eight- to tenfold upregulation of ets-1 was observed in PTC and three- to fourfold upregulation of ets-1 was observed in FTC (and GD) compared with benign thyroid nodules and normal thyroid tissues. In addition, thyroglobulin mRNA expression was markedly downregulated (50- to 100-fold) in FTC, PTC and GD samples compared with benign nodular and normal thyroid tissues. Hence an ets-1/Tg ratio >20 distinguished differentiated thyroid cancer from benign nodular or normal thyroid tissue. We then studied ets1- and Tg mRNA expression levels in fine needle aspiration cytology (FNAC) samples. However, in a consecutive series of 40 FNAC samples only equivocal results were obtained on 38 benign and two malignant (FTC) thyroid tumour samples.



Upregulation of ets-1 and downregulation of Tg mRNA expression occur in differentiated thyroid cancer and may facilitate pre-operative identification of thyroid malignancy depending on further evaluation of these potentially promising markers in a larger series of benign and malignant thyroid tumours and their FNAC samples.
Fuhrer
D
D
0000-0003-0357-4192
III Medical Department, University of Leipzig, Ph-Rosenthal-Str. 27, 04103 Leipzig, Germany. fued@medizin.uni-leipzig.de
Eszlinger
M
M
Karger
S
S
Krause
K
K
Engelhardt
C
C
Hasenclever
D
D
Dralle
H
H
Paschke
R
R
D000236:Adenoma / Q000473:pathology / Q000503:physiopathology*; D014408:Biomarkers, Tumor; D051546:Cyclooxygenase 2; D015972:Gene Expression Regulation, Neoplastic; D006111:Graves Disease / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000235:genetics*; D008565:Membrane Proteins; D016133:Polymerase Chain Reaction; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics*; D050784:Proto-Oncogene Protein c-ets-1; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D050783:Proto-Oncogene Proteins c-ets; D012333:RNA, Messenger / Q000032:analysis; D013954:Thyroglobulin / Q000235:genetics*; D013961:Thyroid Gland / Q000473:pathology / Q000502:physiology; D013964:Thyroid Neoplasms / Q000473:pathology / Q000503:physiopathology*; D016606:Thyroid Nodule / Q000473:pathology / Q000503:physiopathology; D014157:Transcription Factors / Q000235:genetics*
D014408:Biomarkers, Tumor; C494041:ETS1 protein, human; D008565:Membrane Proteins; D050784:Proto-Oncogene Protein c-ets-1; D011518:Proto-Oncogene Proteins; D050783:Proto-Oncogene Proteins c-ets; D012333:RNA, Messenger; D014157:Transcription Factors; D007335:Insulin-Like Growth Factor II; D013954:Thyroglobulin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases